Center of Inflammation and Metabolism and Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Chair of Sport and Health Management, Technical University of Munich, Munich, Germany.
JMIR Mhealth Uhealth. 2022 Sep 28;10(9):e30602. doi: 10.2196/30602.
Effective and sustainable implementation of physical activity (PA) in type 2 diabetes (T2D) health care has in general not been successful. Efficacious and contemporary approaches to support PA adherence and adoption are required.
The primary objective of this study was to investigate the effectiveness of including an app-based (InterWalk) approach in municipality-based rehabilitation to increase moderate-and-vigorous PA (MVPA) across 52 weeks compared with standard care among individuals with T2D.
The study was designed as a parallel-group, randomized trial with 52 weeks' intervention and subsequent follow-up for effectiveness (52 weeks from baseline). Participants were recruited between January 2015 and December 2016 and randomly allocated (2:1) into 12 weeks of (1) standard care + InterWalk app-based interval walking training (IWT; IWT group; n=140), or (2) standard care + the standard exercise program (StC group; n=74). Following 12 weeks, the IWT group was encouraged to maintain InterWalk app-based IWT (3 times per week for 30-60 minutes) and the StC group was encouraged to maintain exercise without structured support. Moreover, half of the IWT group (IWTsupport group, n=54) received additional motivational support following the 12-week program until 52-week follow-up. The primary outcome was change in objectively measured MVPA time (minutes/day) from baseline to 52-week follow-up. Key secondary outcomes included changes in self-rated physical and mental health-related quality of life (HRQoL), physical fitness, weight, and waist circumference.
Participants had a mean age of 59.6 (SD 10.6) years and 128/214 (59.8%) were men. No changes in MVPA time were observed from baseline to 52-week follow-up in the StC and IWT groups (least squares means [95% CI] 0.6 [-4.6 to 5.8] and -0.2 [-3.8 to 3.3], respectively) and no differences were observed between the groups (mean difference [95% CI] -0.8 [-8.1 to 6.4] minutes/day; P=.82). Physical HRQoL increased by a mean of 4.3 (95% CI 1.8 to 6.9) 12-item Short-Form Health Survey (SF-12) points more in the IWT group compared with the StC group (Benjamini-Hochberg adjusted P=.007) and waist circumference apparently decreased a mean of -2.3 (95% CI -4.1 to -0.4) cm more in the IWT group compared with the StC group but with a Benjamini-Hochberg adjusted P=.06. No between-group differences were observed among the remaining key secondary outcomes.
Among individuals with T2D referred to municipality-based lifestyle programs, randomization to InterWalk app-based IWT did not increase objectively measured MVPA time over 52 weeks compared with standard health care, although apparent benefits were observed for physical HRQoL.
ClinicalTrials.gov NCT02341690; https://clinicaltrials.gov/ct2/show/NCT02341690.
在 2 型糖尿病(T2D)的医疗保健中,有效且可持续地实施身体活动(PA)通常并不成功。需要有效的、现代的方法来支持 PA 的坚持和采用。
本研究的主要目的是调查在市级康复中纳入基于应用程序(InterWalk)的方法与标准护理相比,在 52 周内增加 T2D 患者的中度至剧烈体力活动(MVPA)的效果。
该研究设计为平行组、随机试验,干预时间为 52 周,随后进行有效性随访(从基线开始的 52 周)。参与者于 2015 年 1 月至 2016 年 12 月招募,并随机分为 12 周(1)标准护理+InterWalk 基于应用程序的间歇步行训练(IWT;IWT 组;n=140)或(2)标准护理+标准运动方案(StC 组;n=74)。12 周后,鼓励 IWT 组继续进行基于应用程序的 IWT(每周 3 次,每次 30-60 分钟),并鼓励 StC 组在没有结构化支持的情况下继续运动。此外,IWT 组的一半(IWTsupport 组,n=54)在 12 周计划结束后至 52 周随访期间接受额外的动机支持。主要结局是从基线到 52 周随访期间,客观测量的 MVPA 时间(分钟/天)的变化。关键次要结局包括自我评估的身体和心理健康相关生活质量(HRQoL)、体能、体重和腰围的变化。
参与者的平均年龄为 59.6(SD 10.6)岁,128/214(59.8%)为男性。在 StC 和 IWT 组中,从基线到 52 周随访期间,MVPA 时间均未发生变化(最小二乘均值[95%CI]0.6[-4.6 至 5.8]和-0.2[-3.8 至 3.3]),两组之间也未观察到差异(平均差异[95%CI]-0.8[-8.1 至 6.4]分钟/天;P=.82)。IWT 组的 12 项简短健康调查(SF-12)身体 HRQoL 平均增加 4.3(95%CI 1.8 至 6.9)点,比 StC 组高(Benjamini-Hochberg 调整后 P=.007),而 IWT 组的腰围平均减少 2.3(95%CI 4.1 至 0.4)cm,比 StC 组低,但 Benjamini-Hochberg 调整后 P=.06。两组之间在其他关键次要结局方面没有观察到差异。
在被转诊到市级生活方式项目的 T2D 患者中,与标准保健相比,随机分配到基于应用程序的 IWT 并没有增加客观测量的 MVPA 时间,尽管在身体 HRQoL 方面观察到明显的益处。
ClinicalTrials.gov NCT02341690;https://clinicaltrials.gov/ct2/show/NCT02341690。